Pharmaco - Press Releases

Date	Title	Company
17-Aug-2022	Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: DEFENCE’S ACCUMTM VARIANT 'A1' CONVERTS MESENCHYMAL STROMAL CELLS INTO POTENT ANTIGEN PRESENTING CELLS SUITABLE FOR CANCER VACCINATION	Defence Therapeutics Inc.
17-Aug-2022	Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access	Relief Therapeutics Holding SA
16-Aug-2022	Abivax announces a change in its governance	ABIVAX
16-Aug-2022	New BioPure Braided Hose assemblies offer a total solution for bulk fluid transfer in critical bioprocess fluid transfer applications	Sciad Newswire
16-Aug-2022	IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award	IQVIA
16-Aug-2022	OKYO Pharma Limited - Final audited results for the year ended 31 March 2022	OKYO Pharma Limited
16-Aug-2022	Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study	Formycon AG
16-Aug-2022	Straumann Group reports over CHF 1 billion in the first half of 2022	Straumann Holding AG
16-Aug-2022	Medartis reports 20% sales growth and makes further progress in strengthening its US organisation	Medartis Holding AG
15-Aug-2022	Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK	Moderna, Inc.
15-Aug-2022	Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG	Epigenomics AG
12-Aug-2022	Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million	Heidelberg Pharma AG
12-Aug-2022	Q2/2022: Sales of EUR 2.7 million and EBITDA of EUR -0.2 million below expectations in persistently challenging macroeconomic environment; growth expected for second half of 2022	aap Implantate AG
12-Aug-2022	Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease	Relief Therapeutics Holding SA
11-Aug-2022	F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights	F-star Therapeutics
11-Aug-2022	argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis	argenx
11-Aug-2022	MHRA grants marketing authorisation for Novartis’ radioligand therapy Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan) in advanced prostate cancer in Great Britain	Novartis
11-Aug-2022	Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy	Nouscom
11-Aug-2022	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update	iTeos
11-Aug-2022	Genmab Announces Financial Results for the First Half of 2022	Genmab